Handa Pharmaceuticals, Inc. (TPEX:6620)
75.60
-0.40 (-0.53%)
Apr 29, 2026, 1:30 PM CST
Handa Pharmaceuticals Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 1,807 | 597.38 | 667.05 | 365.91 | 263.31 | Upgrade
|
| Short-Term Investments | 1,896 | 1,232 | 1,650 | - | 19.96 | Upgrade
|
| Cash & Short-Term Investments | 3,704 | 1,829 | 2,317 | 365.91 | 283.27 | Upgrade
|
| Cash Growth | 102.45% | -21.04% | 533.18% | 29.18% | -10.10% | Upgrade
|
| Accounts Receivable | 580.02 | 190.44 | 376.37 | 153.48 | 7.79 | Upgrade
|
| Other Receivables | 6.49 | 29.29 | 6.74 | 8.02 | 7.62 | Upgrade
|
| Receivables | 586.51 | 219.73 | 383.11 | 161.51 | 15.4 | Upgrade
|
| Inventory | - | 41.24 | - | - | - | Upgrade
|
| Prepaid Expenses | 17.36 | 12.16 | 11.63 | 2.42 | 2.33 | Upgrade
|
| Other Current Assets | 4.79 | 2.66 | 3.27 | 63.02 | 13.34 | Upgrade
|
| Total Current Assets | 4,312 | 2,105 | 2,715 | 592.86 | 314.33 | Upgrade
|
| Property, Plant & Equipment | 84.86 | 75.78 | 21.03 | 43.04 | 41.83 | Upgrade
|
| Long-Term Investments | 59.93 | 62.2 | 61.86 | - | - | Upgrade
|
| Goodwill | 35.89 | 35.93 | 34.95 | 34.95 | 34.95 | Upgrade
|
| Other Intangible Assets | 730.49 | 917.05 | 0.59 | 1.07 | 1.31 | Upgrade
|
| Long-Term Deferred Tax Assets | 266.28 | 243.52 | 202.85 | 117.23 | 105.18 | Upgrade
|
| Other Long-Term Assets | 402.8 | 1.72 | 1.04 | 1.43 | 0.93 | Upgrade
|
| Total Assets | 5,893 | 3,441 | 3,037 | 790.56 | 498.53 | Upgrade
|
| Accounts Payable | 30.23 | 20.78 | 13.97 | 6.22 | 1.08 | Upgrade
|
| Accrued Expenses | 53.51 | 33.29 | 51.38 | 18.53 | 14.61 | Upgrade
|
| Current Portion of Leases | 10.22 | 7.27 | 5.57 | 10.14 | 6.2 | Upgrade
|
| Current Income Taxes Payable | 14.43 | - | 124.76 | 1.34 | 0.01 | Upgrade
|
| Other Current Liabilities | 9.45 | 180.02 | 13.81 | 9.13 | 7.84 | Upgrade
|
| Total Current Liabilities | 117.84 | 241.36 | 209.49 | 45.35 | 29.73 | Upgrade
|
| Long-Term Leases | 37.41 | 32.83 | 7.67 | 19.46 | 5.7 | Upgrade
|
| Long-Term Unearned Revenue | 27.71 | 42.62 | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | 10.1 | 7.28 | 23.81 | 4.63 | - | Upgrade
|
| Other Long-Term Liabilities | 39 | - | 39.92 | - | - | Upgrade
|
| Total Liabilities | 232.05 | 324.09 | 280.88 | 69.44 | 35.43 | Upgrade
|
| Common Stock | 1,700 | 1,412 | 1,411 | 1,302 | 1,221 | Upgrade
|
| Additional Paid-In Capital | 3,094 | 1,254 | 1,253 | 579.02 | 338.41 | Upgrade
|
| Retained Earnings | 1,058 | 546.87 | 215.2 | -1,089 | -1,049 | Upgrade
|
| Treasury Stock | -114.4 | -56.52 | - | - | - | Upgrade
|
| Comprehensive Income & Other | -77.26 | -39.45 | -123.18 | -70.76 | -47.93 | Upgrade
|
| Shareholders' Equity | 5,660 | 3,117 | 2,756 | 721.12 | 463.1 | Upgrade
|
| Total Liabilities & Equity | 5,893 | 3,441 | 3,037 | 790.56 | 498.53 | Upgrade
|
| Total Debt | 47.64 | 40.1 | 13.24 | 29.59 | 11.89 | Upgrade
|
| Net Cash (Debt) | 3,656 | 1,789 | 2,304 | 336.32 | 271.38 | Upgrade
|
| Net Cash Growth | 104.32% | -22.33% | 584.95% | 23.93% | -10.06% | Upgrade
|
| Net Cash Per Share | 23.54 | 12.68 | 17.10 | 2.68 | 2.31 | Upgrade
|
| Filing Date Shares Outstanding | 165.53 | 140.48 | 141.09 | 130.16 | 122.13 | Upgrade
|
| Total Common Shares Outstanding | 165.53 | 140.48 | 141.09 | 130.16 | 122.13 | Upgrade
|
| Working Capital | 4,194 | 1,864 | 2,505 | 547.5 | 284.61 | Upgrade
|
| Book Value Per Share | 34.20 | 22.19 | 19.54 | 5.54 | 3.79 | Upgrade
|
| Tangible Book Value | 4,894 | 2,164 | 2,721 | 685.11 | 426.85 | Upgrade
|
| Tangible Book Value Per Share | 29.57 | 15.41 | 19.28 | 5.26 | 3.50 | Upgrade
|
| Machinery | 51.86 | 60.95 | 55.98 | 66.98 | 76.07 | Upgrade
|
| Leasehold Improvements | 15.32 | 15.3 | 12.64 | 15.54 | 15.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.